This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Understand the Main CMC Challenges to Improve ATMP Development
Published on: Apr 5th, 2018
Recent clinical successes in cell therapy and gene therapy have shown how fast this field is advancing. While the clinical outcomes are leading the developments in this field, the chemistry, manufacturing, and control (CMC) are struggling to meet development needs, global regulatory compliance and timelines.
The intricacies of these advanced therapies represent many challenges. From cell source to the final product, sponsors are continuously addressing gaps to improve the product quality and deliver a safe and efficacious product. In this webinar, we will focus on the main CMC challenges in cell and gene therapy development in the EU and US and their integration as part of the overall product development.
Key takeaway message:
Present specific quality considerations for cell and gene therapies
Identify and take into account the CMC challenges during product development in order to minimize CMC hurdles
Provide insight on commonalities and differences between EU and US
SAMPLE OF THE WEBINAR
Understand the Main CMC Challenges to Improve ATMP Development
Access the full webinar replay now
Fill in the form to download the content